It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

Legal & General fired up its shares today by announcing a major deal to streamline its US operations.The tie-up with Japan’s ...